Atorvastatin in Pulmonary Hypertension

Phase 2 Completed 220 enrolled Chinese Academy of Medical Sciences, Fuwai Hospital Capital Development Scientific Fund · collab National Grant from The Ministry of Science and Technology · collab

RandomizedParallel-groupQuadruple-blindTreatment

Summary

Clinical effect and tolerability of atorvastatin versus placebo in patients with Pulmonary Hypertension: double-blinded, randomised, prospective phase II study for 6 months with adjusted doses of Atorvastatin

Timeline

Start: 2007-02
Primary completion: 2010-03
Completion: 2010-05

Publications

Zeng WJ, Xiong CM, Zhao L, Shan GL, Liu ZH, Xue F, Gu Q, Ni XH, Zhao ZH, Cheng XS, Wilkins MR, He JG; Atorvastatin in Pulmonary Arterial Hypertension (APATH) Study Group. Atorvastatin in pulmonary arterial hypertension (APATH) study. Eur Respir J. 2012 Jul;40(1):67-74. doi: 10.1183/09031936.00149011. Epub 2012 Feb 23.

Drugs

Evaluation	Drug	Modality	Dose	Route
Comparator	Atorvastatin	Small molecule	10 mg	—

Atorvastatin in Pulmonary Hypertension

Summary

Timeline

Publications

Drugs

Indications